This outcome holds significant potential for enhancing patient compliance and reducing hospitalization costs for individuals with type 1 and type 2 diabetes mellitus (DM), who typically require daily insulin injections to maintain stable blood glucose levels [64]. This evidence concerns the gene INS and diabetes mellitus.